LGALS1 and cancer: By inhibiting leukocyte motility and activation (Norling et al., 2008; Cooper et al., 2010), Gal-1 regulates different types of immune responses, from immune-tolerance, exploited by cancer cells, to acute and chronic inflammation (Sundblad et al., 2017; Chou et al., 2018).